Australia's Mesoblast hits over two week high on upbeat Ryoncil revenue

Mesoblast

10/07/2026 05:50

** Shares of Mesoblast MSB.AX rise 7.9% to A$2.265, their highest level since June 24
** On track for best day since April 15 if gains hold
** The drug-maker's cell therapy Ryoncil reports quarterly net revenue of $36 million, up from $30.3 million in last qtr
** About 5.8 mln shares change hands, 1.8x the 30-day average of 3.3 mln; busiest trading day since June 26
** Stock down 16.5% YTD including moves in current session

 (Reporting by Jasmeen Ara Shaikh in Bengaluru)
 ((Jasmeenaraislam.Shaikh@thomsonreuters.com;))